Synonyms
Asthma drugs; Asthma management; Asthma medications; Asthma pharmacology
Introduction
Asthma is a disease of variable airflow obstruction resulting from inflammatory cell infiltration and smooth muscle constriction of the small airways of the lungs. These effects have the potential to cause chronic changes, structural remodeling, and an increase in smooth muscle mass which can contribute to future episodes of obstruction (Fanta 2009). The symptoms of airway hyper-responsiveness and obstruction manifest as recurrent episodic breathlessness and wheeze, associated with cough, particularly at night (Global Strategy for Asthma Management and Prevention 2014). The prevalence of asthma and atopy continues to increase but there has been a decrease in the number of severe exacerbations and mortality (Fanta 2009).
Asthma is one of the most common chronic diseases of childhood (Porter 2012), and genetic and environmental agents contribute to the disease evolution (Busse and Lemanske 2001...
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Barnes, P. J. (2003). Theophylline. American Journal of Respiratory and Critical Care Medicine, 167(6), 813–818.
British Thoracic Society. (2012). British Guideline on the management of asthma: A National Clinical Guideline. Edinburgh. https://www.brit-thoracic.org.uk/guidelines-and-quality-standards/asthma-guideline/
Busse, W. W., & Lemanske, R. F., Jr. (2001). Asthma. New England Journal of Medicine, 344(5), 350–362.
Fanta, C. (2009). Asthma. New England Journal of Medicine, 360(10), 1002–1014.
Global Strategy for Asthma Management and Prevention. (2014). http://www.ginasthma.org/local/uploads/files/GINA_Pocket_2014_Jun11.pdf
Kostadima, E., Tsiodras, S., Alexopoulos, E. I., Kaditis, A. G., Mavrou, I., Georgatou, N., et al. (2004). Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma. European Respiratory Journal, 23(5), 714–717.
McDonald, N. J., & Bara, A. I. (2003). Anticholinergic therapy for chronic asthma in children over two years of age. Cochrane Database of Sysematic Reviews, (3), CD003535.
Mohammed, S., & Goodacre, S. (2007). Intravenous and nebulised magnesium sulphate for acute asthma: Systematic review and meta-analysis. Emergency Medicine Journal, 24(12), 823–830.
National Asthma Council of Australia. (2014). The asthma management handbook. http://www.asthmahandbook.org.au/resources/medicines-guide/preventers/montelukast
National Heart Lung and Blood Institute. (2007). Expert panel report 3: Guidelines for the diagnosis and management of asthma National Asthma Education and Prevention Program. Bethesda: Department of Health and Human Services. www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf
Porter, R. S. (Ed.). (2012). The Merck manual for healthcare professionals. New Jersey: Merck Sharp and Dohme Corp. www.merckmanuals.com/professional/pulmonary_disorders
Rodrigo, G. J., & Castro-Rodriguez, J. A. (2005). Anticholinergics in the treatment of children and adults with acute asthma: A systematic review with meta-analysis. Thorax, 60(9), 740–746.
Skoner, D. P. (2002). Balancing safety and efficacy in pediatric asthma management. Pediatrics, 109(Suppl E1), 381–392.
Westby, M., Benson, M., & Gibson, P. (2004). Anticholinergic agents for chronic asthma in adults. Cochrane Database of Systematic Reviews, (3), CD003269.
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Crown Copyright
About this entry
Cite this entry
Prentice, B., Jaffe, A., Thomas, P.S. (2016). Anti-asthma Drugs, Overview. In: Parnham, M.J. (eds) Compendium of Inflammatory Diseases. Springer, Basel. https://doi.org/10.1007/978-3-7643-8550-7_6
Download citation
DOI: https://doi.org/10.1007/978-3-7643-8550-7_6
Published:
Publisher Name: Springer, Basel
Print ISBN: 978-3-7643-8530-9
Online ISBN: 978-3-7643-8550-7
eBook Packages: Biomedical and Life SciencesReference Module Biomedical and Life Sciences